Sharon L. Giles1, Veronica A. Morgan1, Sophie F. Riches2, Karen Thomas3, Chris Parker4,5, Nandita M. De Souza1,2
1Clinical Magnetic Resonance Unit, Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK; 2Clinical Magnetic Resonance Unit, Institute of Cancer Research, Sutton, Surrey, UK; 3Clinical Research & Development, Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK; 4Academic Urology, Institute of Cancer Research, Sutton, Surrey, UK; 5Academic Urology, Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK
This study investigates ADC as a predictive biomarker in prostate cancer progression. Mean ADC measurements of tumor in 81 patients on active surveillance were calculated for all b values (ADCoverall), and with only low b values (0-300, ADCfast) and high b values (300-800, ADCslow). ADCs in those whose repeat biopsies were upgraded vs. stable at follow-up were compared. Coxs regression was used to predict likelihood of progression to radical treatment. Both ADC components were significantly lower in those that were histologically upgraded at repeat biopsy. True diffusion, ADCslow, was a significant predictor of progression to radical treatment.
Keywords